ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA

Rosen Law Firm announces a securities class action lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges the company made materially false statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls. The deadline to serve as lead plaintiff is August 10, 2026.

07/31/2026, 3:56 PM • GlobeNewswire

AUGUST 10, 2026 INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

ADMA Biologics faces a securities class action lawsuit alleging the company made false statements about revenue growth through channel stuffing and undisclosed related party transactions. A Culper Research report claimed ADMA's reported 20% growth in 2025 was actually -3% when adjusted for extended payment terms. The stock declined over 16% following the report, and another 13% after a Cantor Fitzgerald downgrade. Investors with substantial losses can seek lead plaintiff status by August 10, 2026.

07/31/2026, 6:55 AM • GlobeNewswire

MONDAY DEADLINE: GeneDx Holdings Corp. (WGS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

GeneDx Holdings Corp. (WGS) investors with substantial losses have until August 3, 2026 to seek appointment as lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that GeneDx made false and misleading statements regarding the viability of its Fabric Genomics acquisition. GeneDx's stock dropped over 49% on May 4, 2026 after revealing a significant drop in adjusted gross margin from 74% to 69%, reduced earnings projections, and a $31.3 million impairment loss directly attributable to Fabric Genomics.

07/31/2026, 6:55 AM • GlobeNewswire

$ADMA Securities: Suffer Losses on Your ADMA Biologics Investment? BFA Law Reminds Investors of the Securities Fraud Lawsuit to Recover Losses

ADMA Biologics faces a securities fraud class action lawsuit after its stock plummeted following Culper Research's allegations of channel stuffing. The company allegedly inflated its 2025 revenue growth from -3% to +20% by inducing distributors to overstock its flagship product ASCENIV through rebates and extended payment terms. The stock dropped 29% cumulatively following the March 2026 revelations and subsequent analyst downgrades.

07/31/2026, 6:47 AM • GlobeNewswire

ADMA 10-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– HBSS

A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly misrepresenting its financial condition, engaging in channel stuffing, undisclosed related-party transactions, and lacking adequate internal controls. The allegations were exposed by a Culper Research short-seller report on March 24, 2026, causing the stock to plunge 31.6% over two trading days. Investors with substantial losses are urged to contact Hagens Berman by the August 10, 2026 deadline to participate in the class action.

07/30/2026, 8:07 PM • GlobeNewswire

ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

ADMA Biologics faces a securities class action lawsuit for allegedly failing to disclose material information between August 2024 and March 2026. The company is accused of undisclosed related party transactions, channel stuffing, inadequate internal controls, and making false statements about its business operations and prospects. Investors with losses exceeding $100,000 have until August 10, 2026 to file lead plaintiff applications.

07/30/2026, 11:52 AM • GlobeNewswire

ADMA BIOLOGICS DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

Rosen Law Firm announces a securities class action lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges the company made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. The lead plaintiff deadline is August 10, 2026.

07/28/2026, 3:37 PM • GlobeNewswire

Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

ADMA Biologics faces a class action securities fraud lawsuit after Culper Research alleged channel stuffing and undisclosed related party transactions. The company allegedly induced distributors to stock excess inventory using rebates and extended payment terms to artificially inflate revenue growth. ADMA's stock fell 29.1% following the report. The deadline to file a lead plaintiff motion is August 10, 2026.

07/24/2026, 3:41 PM • GlobeNewswire

ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– HBSS

A securities fraud class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) alleging the company artificially inflated stock value through misrepresentations regarding financial condition, revenue recognition, and undisclosed related-party transactions. A March 2026 short-seller report exposed channel stuffing and undisclosed distributor Genesis BioPharma, causing the stock to plunge 31.6% over two trading days. Investors with substantial losses are urged to contact Hagens Berman by the August 10, 2026 lead plaintiff deadline.

07/24/2026, 1:58 PM • GlobeNewswire

ADMA BIOLOGICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges ADMA Biologics, Inc. Stockholders to Contact the Firm Regarding Their Rights Before August 10th

A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements about its business operations. The lawsuit claims the company engaged in undisclosed related party transactions, used channel stuffing to inflate revenues, and lacked adequate internal controls. Following a short report by Culper Research on March 24, 2026, ADMA's stock fell 16.63%. Investors who purchased shares between August 9, 2024 and March 25, 2026 can join the lawsuit with a deadline of August 10, 2026.

07/23/2026, 5:54 PM • GlobeNewswire

ADMA Alert: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed

A securities fraud class action has been filed against ADMA Biologics (NASDAQ: ADMA) for allegedly making false statements about its financial condition and business practices. The lawsuit claims the company engaged in undisclosed related-party transactions, channel stuffing, and lacked adequate internal controls. A Culper Research short-seller report in March 2026 exposed these allegations, causing the stock to plunge 31.6% over two trading days, with further declines following an ADMA response and analyst downgrade.

07/22/2026, 7:33 PM • GlobeNewswire

ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges ADMA engaged in undisclosed related party transactions, channel stuffing, and lacked adequate internal controls, resulting in materially false statements about the company's business and operations.

07/22/2026, 3:48 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines – ADMA

Pomerantz Law Firm has filed class action lawsuits against ADMA Biologics, Lucid Group, and Nano-X Imaging, alleging securities fraud and unlawful business practices. ADMA's stock declined significantly following a short report alleging channel stuffing and inflated revenue figures, with additional losses after a downgrade from Cantor Fitzgerald.

07/21/2026, 1:51 PM • GlobeNewswire

INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead ADMA Investor Class Action Lawsuit – RGRD Law

A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements regarding revenue growth. A short-seller report claimed the company engaged in channel stuffing and used an undisclosed related party distributor, with actual 2025 revenue declining 3% versus reported 20% growth. The stock fell 16% following the report and an additional 13% after a Cantor Fitzgerald downgrade.

07/20/2026, 5:50 PM • GlobeNewswire

DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against four publicly-traded companies: BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. The complaints allege that defendants made false or misleading statements regarding their business operations, financial performance, and prospects. Investors have until August 7-10, 2026 to file lead plaintiff motions.

07/20/2026, 1:57 PM • GlobeNewswire